Focus: Circle Pharma is a 2024-founded pharmaceutical company headquartered in South San Francisco specializing in macrocyclic therapeutics across oncology, metabolic diseases, and cardiovascular indications. The company is publicly listed but remains in early clinical stage with only one Phase 1 program.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Circle Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Circle Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Circle Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Circle Pharma to Present New Clinical and Preclinical Data at AACR 2026 - Business Wire
Circle Pharma to Present New Clinical and Preclinical Data at AACR 2026 Business Wire
Circle Pharma Announces Publication in Journal of Medicinal Chemistry Highlighting Optimization of First-in-Class Oral Cyclin A/B RxL Inhibitors - Yahoo Finance
Circle Pharma Announces Publication in Journal of Medicinal Chemistry Highlighting Optimization of First-in-Class Oral Cyclin A/B RxL Inhibitors Yahoo Finance
Circle Pharma Announces Publication in Journal of Medicinal Chemistry Highlighting Optimization of First-in-Class Oral Cyclin A/B RxL Inhibitors - Business Wire
Circle Pharma Announces Publication in Journal of Medicinal Chemistry Highlighting Optimization of First-in-Class Oral Cyclin A/B RxL Inhibitors Business Wire
Circle Pharma to Participate in Upcoming Investor Conferences - Business Wire
Circle Pharma to Participate in Upcoming Investor Conferences Business Wire
Circle Pharma to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
Circle Pharma to Present at the 44th Annual J.P. Morgan Healthcare Conference Business Wire
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 8 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo